Margarita Chavez

Aligos is a biopharmaceutical company developing targeted therapeutics to address unmet medical needs in liver and viral diseases including MASH, CHB and COVID-19.

ReAx is a Chicago-based, pre-clinical company that is applying next generation chemical proteomic platforms to discover, optimize and validate small molecules directly in cells. The ReAx pipeline enables interrogation of proteomic ‘dark matter’ – a landscape that is rarely studied, much less exploited for ligand discovery against high-value protein targets. By integrating our platforms with innovative chemistry, disease biology, and computational methods, we hope to deliver first-in-class therapeutics in oncology and immunological disease indications.

We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases

Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinsons Research (MJFF).

2022 Impact Report: https://p33chicago.com/velocity2022/ P33 is committed to reclaiming Chicago's position as the World's Brightest Spot for technological discovery and development. We are a team of thinkers and doers – business and community leaders, entrepreneurs, educators, technology experts and policymakers – who represent today's establishment and tomorrow's vanguard. Our work is focused on the key areas that will drive the future of Chicago's technology leadership: Talent & Education, Capital & Finance, Business, Community & Culture, and Government & Infrastructure. Together, we're harnessing the spirit of technological innovation that lives in Chicago to drive momentum for businesses, both emerging and established, as well as for all people of Chicago.

Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company was launched by a $31 million Series A investment by Accelerator Life Science Partners in 2018 and was co-founded by world-class researchers at The University of Texas MD Anderson Cancer Center. The company endeavors to make life-changing medicines for the benefit of patients and their families suffering from serious CNS diseases. The company’s offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science campus.

Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases and immune-mediated diseases. Jnana’s wholly owned lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, for the treatment of phenylketonuria (PKU), a rare genetic metabolic disease. Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures and AbbVie Ventures. For more information, please visit www.jnanatx.com and follow us on Twitter and on LinkedIn.

Carisma Therapeutics is a clinical stage biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages to transform the treatment of cancer and other serious illness.

The NEVCA fosters a collaborative, inclusive, and prosperous innovation ecosystem on behalf of New Englands VC industry. Operating across four pillars - Venture Community, Regional Brand, Workforce Development, and Public Policy - the associations initiatives impact the community at large: events connect founders, funders, and innovators; legislative advocacy promotes economic growth; programs bolster professional development across the venture landscape.

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohns disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Aligos is a biopharmaceutical company developing targeted therapeutics to address unmet medical needs in liver and viral diseases including MASH, CHB and COVID-19.

Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. We are committed to delivering innovative treatments to improve the quality of life for patients with CNS disorders. Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union and Switzerland (both 2015) as well as in the U.S. (2017) and is commercialized in Europe by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the US. Valeo Pharma holds the commercialization rights for the Canadian market, Seqirus for Australia & New Zealand, and Medison for Israel. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indications. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, under the trading symbol NWRN, on the primary market of the Düsseldorf Stock Exchange and on XETRA, trading symbol NP5.

Founded in 1851, Santa Clara University sits in the heart of Silicon Valley—the world’s most innovative and entrepreneurial region. The University’s stunningly landscaped 106-acre campus is home to the historic Mission Santa Clara de Asís. Ranked among the top 15 percent of national universities by U.S. News & World Report, SCU has among the best four-year graduation rates in the nation and is rated by PayScale in the top 1 percent of universities with the highest-paid graduates. SCU has produced elite levels of Fulbright Scholars as well as four Rhodes Scholars. With undergraduate programs in arts and sciences, business, and engineering, and graduate programs in six disciplines, the curriculum blends high-tech innovation with social consciousness grounded in the tradition of Jesuit, Catholic education.

ReAx is a Chicago-based, pre-clinical company that is applying next generation chemical proteomic platforms to discover, optimize and validate small molecules directly in cells. The ReAx pipeline enables interrogation of proteomic ‘dark matter’ – a landscape that is rarely studied, much less exploited for ligand discovery against high-value protein targets. By integrating our platforms with innovative chemistry, disease biology, and computational methods, we hope to deliver first-in-class therapeutics in oncology and immunological disease indications.

We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases